Highest-materiality recent filing
Artiva CFO departs; CEO assumes financial duties; Miralles becomes President
CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.
71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.
Artiva Biotherapeutics raises ~$300M in common stock and pre-funded warrant offering
Priced 23,871,526 shares at $11.52/share and 2,170,138 pre-funded warrants at $11.5199 each.
Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027
Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.
Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA
Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.
32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.
On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026
On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.
On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026
Max materiality 0.85 · Median 0.60 · Most common event other_material